Background: The Trail Making Test (TMT) Part A (TMT-A) is a good measure of performance on cognitive processing speed. This study aimed to perform a genome-wide association study of TMT-A in Alzheimer's disease (AD).
Methods: A total of 757 individuals with TMT-A phenotypes and 620,901 single nucleotide polymorphisms (SNPs) were extracted from the Alzheimer's Disease Neuroimaging Initiative 1 (ADNI-1) cohort. AD related cognitive phenotypes include TMT-A, TMT-B, Functional Activities Questionnaire (FAQ), Clinical Dementia Rating Sum of Boxes (CDR-SB), and Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS13). Multivariable linear regression analysis of TMT-A was conducted using PLINK software. The most TMT-A associated gene was tested with Color Trails Test 1 Form A (CTTA), a culturally fair analog of the TMT-A. Functional annotation of SNPs was performed using the RegulomeDB and Genotype-Tissue Expression (GTEx) databases.
Results: The best signal with TMT-A was rs1108010 (p = 4.34 × 10) at 11p15.2 within INSC gene, which was also associated with TMT-B, FAQ, CDR-SB, and ADAS13 (p = 2.47 × 10, 8.56 × 10, 0.0127 and 0.0188, respectively). Furthermore, suggestive loci were identified such as FOXD2 and CLTA with TMT-A, GBP1/GBP3 with TMT-B, GRIK2 with FAQ, BAALC and CCDC146 with CDR-SB, BAALC and NKAIN2 with ADAS13. Additionally, the best SNP within INSC associated with CTTA was rs7931705 (p = 6.15 × 10). Several SNPs had significant eQTLs using GTEx.
Conclusions: We identified several genes/loci associated with TMT-A and AD related phenotypes. These findings offer the potential for new insights into the pathogenesis of cognitive function and Alzheimer's disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pnpbp.2021.110393 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exosomes and non-coding RNAs: bridging the gap in Alzheimer's pathogenesis and therapeutics.
Metab Brain Dis
January 2025
Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, 530000, China.
Alzheimer's disease (AD) is a neurodegenerative disease that primarily affects the elderly population and is the leading cause of dementia. Meanwhile, the vascular hypothesis suggests that vascular damage occurs in the early stages of the disease, leading to neurodegeneration and hindered waste clearance, which in turn triggers a series of events including the accumulation of amyloid plaques and Tau protein tangles. Non-coding RNAs (ncRNAs), including long noncoding RNAs (lncRNAs), microRNAs (miRNAs), and circular RNAs (circRNAs), have been found to be involved in the regulation of AD.
View Article and Find Full Text PDFMapping the knowledge landscape of the PET/MR domain: a multidimensional bibliometric analysis.
Eur J Nucl Med Mol Imaging
January 2025
Huashan Hospital and Human Phenome Institute, Fudan University, 220 Handan Road, Shanghai, 200433, China.
Objective: This study aims to conduct a bibliometric analysis to explore research trends, collaboration patterns, and emerging themes in the PET/MR field based on published literature from 2010 to 2024.
Methods: A detailed literature search was performed using the Web of Science Core Collection (WoSCC) database with keywords related to PET/MR. A total of 4,349 publications were retrieved and analyzed using various bibliometric tools, including VOSviewer and CiteSpace.
Exploring SERPINA3 as a neuroinflammatory modulator in Alzheimer's disease with sex and regional brain variations.
Metab Brain Dis
January 2025
Department of Biomedical and Biotechnological Sciences, Human Anatomy and Histology Section, School of Medicine, University of Catania, Catania, Italy.
SERPINA3, a serine protease inhibitor, is strongly associated with neuroinflammation, a typical condition of AD. Its expression is linked to microglial and astrocytic markers, suggesting it plays a significant role in modulating neuroinflammatory responses. In this study, we examined the SERPINA3 expression levels, along with CHI3L1, in various brain regions of AD patients and non-demented healthy controls (NDHC).
View Article and Find Full Text PDFThe link between eye movements and cognitive function in mild to moderate Alzheimer's disease.
Exp Brain Res
January 2025
Department of Neurology and Suzhou Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, No. 1055, Sanxiang Road, Suzhou, 215004, Jiangsu Province, People's Republic of China.
This study investigated the relationship between eye movement parameters and cognitive function in patients with mild to moderate Alzheimer's disease (AD). A total of 80 patients with AD (mild and moderate) and 34 normal controls (NC) participated. Neuropsychological assessments were conducted using the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA), while eye movements were recorded using eye-tracking technology.
View Article and Find Full Text PDFAlzheimer's disease and diabetes-associated cognitive dysfunction: the microglia link?
Metab Brain Dis
January 2025
Department of Pharmacy, the Second Affiliated Hospital of Shaoyang University, Shaoyang, Hunan, China.
Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β (Aβ) plaques and the aggregation of tau protein, resulting in intense memory loss and dementia. Diabetes-associated cognitive dysfunction (DACD) is a complication of diabetes mellitus, which is associated with decreased cognitive function and impaired memory. A growing body of literature emphasize the involvement of microglia in AD and DACD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!